REP 2165

Drug Profile

REP 2165

Alternative Names: REP 2165 magnesium chelate; REP 2165-Mg

Latest Information Update: 17 Nov 2015

Price : $50

At a glance

  • Originator REPLICor
  • Class Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Preclinical Hepatitis D

Most Recent Events

  • 09 Nov 2015 REPLICor receives patent allowance for methods of combination therapy using immunotherapeutic agents and agents that lower serum HBsAg in USA
  • 05 Oct 2015 Preclinical trials in Hepatitis D in Canada (IV) before October 2015
  • 05 Oct 2015 Phase-II clinical trials in Hepatitis B in Moldova (IV) (Combination therapy) (NCT02565719)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top